IVABRADINE HYDROCHLORIDE (ivabradine) by Amgen is 12. Approved for hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, either are on maximally tolerated doses of beta-blockers. First approved in 2021.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Ivabradine tablets blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial…
Worked on IVABRADINE HYDROCHLORIDE at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit
Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.